Potential new Alzheimer’s drug passes phase 2 trials

American Academy of Neurology Conference: Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12-week study.